Premium
Utility of QDot® bioconjugates in the detection of ERG gene re‐arrangements in prostate cancer
Author(s) -
Nagy Dea,
Nagle Raymond,
Sathyanarayana Ubaradka,
Riley Janice,
Murillo Adrian,
May Eric,
Jiang David,
SantaCruz Ashley,
Richard Jeanne,
Lefever Mark,
Kosmeder Jerry,
Farrell Michael,
Bieniarz Chris,
Miller Phil,
Pestano Gary
Publication year - 2009
Publication title -
the faseb journal
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.709
H-Index - 277
eISSN - 1530-6860
pISSN - 0892-6638
DOI - 10.1096/fasebj.23.1_supplement.lb338
Subject(s) - tmprss2 , prostate cancer , erg , fusion gene , biology , lncap , gene , cancer research , gene expression , computational biology , cancer , microbiology and biotechnology , genetics , medicine , disease , pathology , biochemistry , retinal , covid-19 , infectious disease (medical specialty)
Prostate cancer (PCA) is one of the most prevalent malignancies affecting men worldwide. Recent discovery of ERG gene re‐arrangements in PCA and their strong association with disease progression has therapeutic and diagnostic implications. Gene fusions identified thus far are characterized by 5' genomic regulatory elements ( TMPRSS2), fused to the ETS family of transcription factors (TF), that can lead to over‐expression of oncogenic TF. In this report, we have developed an automated assay that includes novel FISH probes in conjunction with Qdot‐antibody conjugates, to detect the various ERG re‐arrangements. We have shown sensitive and specific detection of gene rearrangements in xenografts, H1660, LnCAP, and VCAP. These data confirmed previous reports of homozygous intronic deletion, no deletion, and varied deletions of 5'ERG region of Chr 21 in the respective xenografts. Imaging with FISH filters we observed robust signal at 20x magnification. This study outlines the development of novel gene probes and fluorescent bioconjugates that enable simultaneous detection of the 5' and 3' ERG translocations in PCA.